Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Analysis of Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
2022-002648-35Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Erasmus MC. Started Nov 2022; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-002648-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002648-35.